Head-To-Head Analysis: Complete Genomics (GNOM) versus Medical Transcription Billing (MTBC)
Complete Genomics (NASDAQ: GNOM) and Medical Transcription Billing (NASDAQ:MTBC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.
This table compares Complete Genomics and Medical Transcription Billing’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Medical Transcription Billing||-29.08%||-40.41%||-15.27%|
This is a summary of recent ratings and target prices for Complete Genomics and Medical Transcription Billing, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Medical Transcription Billing||0||0||1||0||3.00|
Medical Transcription Billing has a consensus target price of $2.75, indicating a potential downside of 1.79%. Given Medical Transcription Billing’s higher possible upside, analysts plainly believe Medical Transcription Billing is more favorable than Complete Genomics.
Valuation & Earnings
This table compares Complete Genomics and Medical Transcription Billing’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Medical Transcription Billing||$24.49 million||1.32||-$8.79 million||($1.05)||-2.67|
Complete Genomics has higher earnings, but lower revenue than Medical Transcription Billing. Medical Transcription Billing is trading at a lower price-to-earnings ratio than Complete Genomics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
2.3% of Medical Transcription Billing shares are owned by institutional investors. 53.7% of Medical Transcription Billing shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Medical Transcription Billing beats Complete Genomics on 6 of the 9 factors compared between the two stocks.
Complete Genomics Company Profile
Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.
Medical Transcription Billing Company Profile
Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform. PracticePro includes practice management software and related tools, which facilitate the day-to-day operation of a medical practice; electronic health records (EHR), which allow its customers to qualify for government incentives; revenue cycle management (RCM) services, which include medical billing, analytics and related services, and mobile Health (mHealth) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services. The Company offers a clearinghouse service, which allows clients to track claim status.
Receive News & Ratings for Complete Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Complete Genomics and related companies with Analyst Ratings Network's FREE daily email newsletter.